Chardan Capital has reiterated its Buy recommendation for Arrowhead Pharmaceuticals (NASDAQ:ARWR), according to Fintel reports dated May 24, 2023. As of May 11, 2023, Arrowhead Pharmaceuticals’ average one-year price target is $63.17, with a low of $27.27 and a high of $94.50. This represents a projected increase of 74.11% from the latest reported closing price of $36.28.
Arrowhead Pharmaceuticals is projected to reach annual revenue of $309 million, an increase of 13.42%, while the projected annual non-GAAP EPS is -1.78. There are currently 587 funds or institutions with positions in Arrowhead Pharmaceuticals, a decrease of 28 owner(s) or 4.55% in the last quarter.
In other news, iShares Core S&P Mid-Cap ETF has increased its portfolio allocation in ARWR by 13.27% over the last quarter, while Vanguard Total Stock Market Index Fund Investor Shares increased its portfolio allocation by 14.84% over the same time period. Meanwhile, Jpmorgan Chase decreased its portfolio allocation in ARWR by 92.50% over the last quarter.
Arrowhead Pharmaceuticals develops RNAi-based therapeutics to treat diseases by silencing genes that cause them. Its RNAi-based therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
Disclaimer: The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
